An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Study Overview

A phase II study for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutation, will test osimertinib with or without ramucirumab. Researchers hope to determine whether combining these drugs is better at controlling this type of cancer than osimertinib alone. To qualify, participants must be adults 18 or older and have locally advanced or metastatic NSCLC with EGFR.

Study Description

A phase II study for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutation, will test osimertinib with or without ramucirumab. Researchers hope to determine whether combining these drugs is better at controlling this type of cancer than osimertinib alone. To qualify, participants must be adults 18 or older and have locally advanced or metastatic NSCLC with EGFR.


  • IRB Number: 1908483160
  • Research Study Identifier: NCT03909334
  • Principal Investigator: Nasser Hanna, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176